Ipsen Korea appoints ex-AstraZeneca exec as new general manager 

Ipsen Korea announced on Monday the appointment of Yang Mi-sun, former director of Oncology Business Unit at AstraZeneca Korea, as its new general manager. 

Yang is a marketing professional with more than 20 years of experience in the pharmaceutical industry, having previously held positions at Gilead Sciences, MSD Korea, and Bayer Korea.

At AstraZeneca Korea, Yang led the expansion of reimbursement for lung cancer drug Tagrisso as the first-line treatment and the health insurance winning of breast cancer drug Enhertu in Korea in partnership with Daiichi Sankyo. At Gilead Sciences, she led the successful launches of the HIV drug Biktarvy, and at MSD Korea, the release of immunotherapy Keytruda.

“Ipsen has achieved remarkable growth globally in recent years in specialty areas such as oncology, rare disease, and neuroscience,” said Yang. ”I will do my best to ensure that Ipsen's new medicines are quickly available to patients in Korea.”

Ipsen Korea's current portfolio includes Carbometrix for kidney cancer, Diphereline for precocious puberty and prostate cancer, and Somatuline for acromegaly and neuroendocrine tumors. The company plans to introduce Bylvay for cholestatic rare liver which has been selected for the government's accelerated approval, reimbursement, and negotiation pilot program in 2023.

Yang graduated from Chung-Ang University College of Pharmacy and holds an MBA from Indiana University Kelley School of Business and an Executive MBA from Sungkyunkwan University.